Top 10 GU Oncology Updates – July 2026

July 2026 delivered a concentrated set of practice-changing and clinically clarifying updates across GU Oncology. The month included a new perioperative standard in muscle-invasive bladder cancer, the first positive phase 3 trial of a HIF-2alpha inhibitor in the adjuvant renal-cell carcinoma setting, longer-term evidence for metastasis-directed therapy in oligometastatic castration-resistant prostate cancer, and several biomarker, cellular therapy, immunotherapy, and negative randomized studies that help define what should—and should not—move into practice.

This selection includes KEYNOTE-B15/EV-304, LITESPARK-022, ARTO, the CHAI histology biomarker, JCOG1403, TRAVERSE, CheckPRO, RADICAL, OMNIVORE, and PLANETTE. Each item below was published, formally issued, or approved during July 2026.

LITESPARK-022: Belzutifan adds DFS benefit after Nephrectomy

Published in The New England Journal of Medicine on July 1, 2026, LITESPARK-022 was a double-blind phase 3 trial of adjuvant pembrolizumab plus the HIF-2alpha inhibitor belzutifan versus pembrolizumab plus placebo in 1,841 patients with resected clear-cell renal-cell carcinoma at increased risk of recurrence after nephrectomy, with or without complete resection of metastatic disease.

Key findings

• At 24 months, disease-free survival was 80.7% with pembrolizumab plus belzutifan versus 73.7% with pembrolizumab alone.
• The combination reduced the risk of disease recurrence or death by 28% (HR 0.72; 95% CI 0.59–0.87).
• Overall survival data were immature at the interim analysis.

The findings demonstrate that adding HIF-2α inhibition to adjuvant PD-1 blockade significantly improves disease-free survival.

Safety

Grade 3 or higher adverse events occurred in 52.1% with the combination and 30.2% with pembrolizumab alone. Anemia occurred in 84.0% of combination-treated patients, including grade 3 or higher anemia in approximately 12%; hypoxia occurred in 7.0%.

Takeaway

In LITESPARK-022, adjuvant pembrolizumab plus belzutifan significantly improved disease-free survival compared with pembrolizumab plus placebo after nephrectomy in patients with clear-cell renal-cell carcinoma at increased risk of recurrence. The combination was associated with a higher incidence of grade 3 or higher adverse events, while overall survival data remained immature.

KEYNOTE-B15/EV-304: perioperative Padcev/Pembro changes MIBC treatment

Published in The New England Journal of Medicine on July 22, 2026, and accompanied by an FDA approval on July 10, KEYNOTE-B15/EV-304 was an international, open-label, phase 3 trial in 808 patients with previously untreated, cisplatin-eligible muscle-invasive bladder cancer who were candidates for radical cystectomy. Patients received perioperative enfortumab vedotin plus pembrolizumab or standard neoadjuvant gemcitabine-cisplatin followed by surgery.

Key findings

• Two-year event-free survival was 79.4% with enfortumab vedotin plus pembrolizumab versus 66.2% with gemcitabine-cisplatin (HR 0.53; 95% CI 0.41–0.70).
• Two-year overall survival was 86.9% versus 81.3%, respectively (HR 0.65; 95% CI 0.48–0.89).
• Pathologic complete response was achieved in 55.8% versus 32.5% of patients.
• The FDA indication now covers adults with MIBC who are candidates for cystectomy, extending the earlier approval beyond cisplatin-ineligible patients.

Safety

Grade 3 or higher adverse events occurred in 75.7% with the antibody-drug conjugate–immunotherapy regimen and 67.2% with chemotherapy. Implementation requires proactive management of rash, peripheral neuropathy, hyperglycemia, pneumonitis, and immune-related toxicity.

Takeaway

A platinum-free perioperative regimen produced superior event-free survival, overall survival, and pathologic complete response compared with neoadjuvant cisplatin-based chemotherapy in cisplatin-eligible MIBC, although grade 3 or higher adverse events were more frequent with enfortumab vedotin plus pembrolizumab.

ARTO: SBRT plus Abiraterone in Oligometastatic mCRPC

The July 2026 issue of The Lancet Oncology reported the long-term, unplanned overall survival analysis of ARTO, an open-label randomized phase 2 trial. The study enrolled 157 men with oligometastatic castration-resistant prostate cancer, defined as three or fewer nonvisceral bone or nodal lesions, and compared abiraterone plus androgen deprivation therapy with or without stereotactic body radiotherapy to all metastatic sites.

Key findings

• After a median follow-up of 53 months, median overall survival was not reached with SBRT and was 50 months in the control group (HR 0.55; 95% CI 0.33–0.92; P=0.021).
• Median biochemical progression-free survival was 44 months with SBRT versus 18 months without SBRT.
• Median radiologic progression-free survival was 44 months versus 17 months, respectively.
• The survival signal was consistent with the previously reported improvement in early disease-control endpoints.

Safety

Grade 3 or higher adverse events were reported in 9 patients in the SBRT arm and 20 patients in the control arm, with no new late safety signal identified.

Takeaway

ARTO strengthens the rationale for metastasis-directed therapy in carefully selected oligometastatic mCRPC. However, overall survival was an unplanned analysis from a small phase 2 trial; confirmatory phase 3 evidence is needed before SBRT to all lesions becomes a universal standard in first-line mCRPC.

CheckPRO: SBRT does not improve IPI/NIVO activity in unselected mCRPC

Published in the Journal for ImmunoTherapy of Cancer in July 2026, CheckPRO/CA209-8TY was a randomized phase 2 trial of nivolumab plus ipilimumab with or without stereotactic body radiotherapy in heavily pretreated metastatic castration-resistant prostate cancer. Ninety-one patients were enrolled and 81 received at least one dose of immune checkpoint therapy and were evaluable for efficacy.

Key findings

• PSA response rates were 21.6% with SBRT and 20.5% without SBRT.
• Objective response rates were 16.7% and 22.2%, respectively.
• Median radiographic progression-free survival was 2.1 months with SBRT and 1.9 months without SBRT.
• Median overall survival was 10.2 months and 9.2 months, respectively.
• The addition of SBRT did not improve any major efficacy endpoint.

Safety

Grade 3 or 4 treatment-related adverse events occurred in approximately one-third of treated patients.

Takeaway

The trial does not support adding SBRT as a general immune-priming strategy to dual checkpoint blockade in unselected mCRPC. The responses observed in a minority of patients reinforce the need to identify biomarkers of response to immune-checkpoint inhibition in mCRPC.

CHAI-Powered Biomarker in mHSPC

Published in JCO Precision Oncology on July 8, 2026, this study developed and independently validated a computational histology artificial intelligence–powered biomarker using digitized hematoxylin-and-eosin slides and participant-level data from two phase 3 trials. The development cohort included 507 patients from CHAARTED, and the validation cohort included 684 patients from ENZAMET.

Key findings

• The model separated patients into favorable and unfavorable histologic-risk groups using the diagnostic slide alone.
• In ENZAMET, five-year overall survival was 69% in the favorable group and 39% in the unfavorable group; the unadjusted OS hazard ratio was approximately 2.6.
• Five-year progression-free survival was 49% versus 24%, respectively; the unadjusted PFS hazard ratio was approximately 2.2.
• The biomarker remained independently prognostic after adjustment for established clinical variables.
• Exploratory analyses suggested greater benefit from treatment intensification in the unfavorable group, but docetaxel use was not randomized within ENZAMET and the predictive finding is not definitive.

Takeaway

CHAI shows that standard pathology slides contain clinically useful prognostic information beyond conventional clinicopathologic risk factors. The platform is promising for risk stratification, but the predictive treatment-intensification finding requires validation in a randomized cohort before it should guide doublet-versus-triplet treatment decisions.

JCOG1403: Intravesical Pirarubicin after nephroureterectomy

Published online in The Lancet Oncology on July 10, 2026, JCOG1403 was a multicenter, open-label, randomized phase 3 trial in 304 patients with stage 0a–III upper tract urothelial carcinoma undergoing radical nephroureterectomy. Patients were assigned to a single intravesical instillation of pirarubicin 30 mg within 24 hours of surgery or observation.

Key findings

• Three-year relapse-free survival was 60.0% with pirarubicin versus 47.0% with observation (HR 0.67; one-sided P=0.0066).
• Bladder recurrence occurred in 25% versus 34% of patients, an absolute reduction of 9 percentage points.
• Three-year overall survival was similar: 89.3% versus 88.4%.
• The intervention was simple, time-limited, and delivered immediately after surgery.

Safety

Grade 3 hematuria occurred in approximately 3% of patients receiving pirarubicin; no treatment-related deaths were reported.

Takeaway

JCOG1403 provides phase 3 evidence that a single intravesical instillation of pirarubicin within 24 hours after radical nephroureterectomy improves relapse-free survival in patients with upper tract urothelial carcinoma, with manageable adverse events.

TRAVERSE: ALLO-316 in clear-cell RCC

Published in the Journal of Clinical Oncology on July 14, 2026, TRAVERSE evaluated a single infusion of ALLO-316, an off-the-shelf allogeneic CD70-targeted CAR T-cell product, in heavily pretreated advanced clear-cell renal-cell carcinoma. The safety population included 50 patients and 46 patients received ALLO-316 and were evaluable for efficacy; the median number of prior systemic lines was four.

Key findings

• Across all 46 treated patients, the confirmed objective response rate was 17.4% and the disease-control rate was 58.7%.
• In the phase Ib cohort, the objective response rate was 25.0%.
• Among phase Ib patients with high CD70 expression, defined as a tumor proportion score of at least 50%, the objective response rate was 31.3%; no responses were observed in the phase Ib CD70-low group.
• In the phase Ib cohort, median duration of response was not estimable, and no progression events occurred among responders after a minimum follow-up of eight months.

Safety

Grade 3–5 treatment-emergent adverse events occurred in 92% of the safety population, most commonly neutropenia, leukopenia, and anemia. Three treatment-related deaths occurred during phase Ia; subsequent phase Ib risk-mitigation measures improved the safety profile, but serious infection and immune-effector-cell toxicities remain central concerns.

Takeaway

TRAVERSE is important proof of concept that an allogeneic CAR T-cell therapy can produce durable responses in a solid tumor, particularly in a biomarker-enriched population. ALLO-316 remains investigational, and larger studies must confirm efficacy, optimize CD70 selection, and demonstrate an acceptable risk-benefit profile.

RADICAL: Radium-223 Plus Cabozantinib in mRCC With Bone Metastases

Published in the Journal of Clinical Oncology on July 27, 2026, RADICAL (Alliance A031801) was a randomized phase 2 trial in 98 patients with metastatic renal-cell carcinoma and at least one bone metastasis. Patients received cabozantinib with or without six cycles of radium-223; symptomatic skeletal event–free survival was the primary endpoint.

Key findings

• The study crossed its prespecified futility boundary and was closed to further enrollment.
• Median symptomatic skeletal event–free survival was 16.7 months with radium-223 plus cabozantinib and 17.6 months with cabozantinib alone (stratified HR 1.46).
• Median progression-free survival was 10.3 versus 10.5 months.
• Objective response rates were 19.4% versus 25.0%, respectively.
• No efficacy subgroup clearly favored the addition of radium-223.

Safety

Grade 3 or higher adverse events occurred in 69.6% with the combination and 75.5% with cabozantinib alone, but hematologic toxicity was more frequent with radium-223.

Takeaway

RADICAL is a useful negative trial. The biological appeal of combining a bone-seeking alpha emitter with a bone-active TKI did not translate into clinical benefit, and radium-223 should not be added to cabozantinib for RCC bone metastases outside a trial.

PLANETTE: Ceralasertib in ATM-Altered mCRPC

Published in Cancer Research Communications in July 2026, the phase 2a PLANETTE study evaluated ceralasertib, an oral ATR inhibitor, in previously treated ATM-altered advanced solid tumors and metastatic castration-resistant prostate cancer. The final analysis included 30 patients in the solid-tumor cohort and 15 patients in the mCRPC cohort; centrally confirmed ATM alterations were present in 28 and 13 patients, respectively.

Key findings

• In the centrally confirmed mCRPC population, the composite response rate was 7.7%, based on one patient with conversion of circulating tumor-cell count from unfavorable to favorable.
• No convincing radiographic response signal emerged in the mCRPC cohort.
• Median progression-free survival was approximately 3.7 months in both study cohorts.
• The initial ceralasertib dose of 240 mg twice daily was not tolerable because of early grade 3–4 hematologic toxicity and was reduced to 160 mg twice daily on days 1–14 of each 28-day cycle.

Safety

At the reduced dose, grade 3 or higher treatment-related adverse events occurred in 33.3% of the mCRPC cohort; anemia, nausea, fatigue, and cytopenias were common.

Takeaway

PLANETTE shows that ATM alteration or ATM protein loss alone is not an adequate stand-alone biomarker for ATR-inhibitor monotherapy. Future development should prioritize improved biomarker selection and rational combinations rather than ceralasertib monotherapy in broadly defined ATM-altered mCRPC.

OMNIVORE Long-Term Follow-Up

Published in the Journal for ImmunoTherapy of Cancer on July 1, 2026, the long-term OMNIVORE analysis evaluated a response-adaptive strategy in advanced renal-cell carcinoma. All patients began nivolumab monotherapy. Patients with an early confirmed response stopped nivolumab and entered observation, whereas patients with stable or progressive disease received two doses of ipilimumab added to ongoing nivolumab.

Key findings

• Of 83 patients who initiated treatment, 12 entered the treatment-discontinuation arm and 57 entered the salvage-ipilimumab arm.
• Three-year overall survival was 64% in the overall cohort, 83% among early responders who discontinued nivolumab, and 63% in the salvage-ipilimumab group.
• Six of 12 early responders remained off nivolumab at one year; five maintained responses for more than 43 months without therapy.
• Response conversion after salvage ipilimumab remained uncommon, consistent with the limited activity reported in the original analysis.

Takeaway

OMNIVORE supports the biological possibility of prolonged treatment-free survival in a small, highly selected group of early responders. It does not establish routine early nivolumab discontinuation, and it confirms that delayed ipilimumab is not an effective substitute for an upfront checkpoint-inhibitor combination in most nonresponders.

The bottom line

July 2026 brought two phase 3 advances in GU oncology: perioperative enfortumab vedotin plus pembrolizumab in cisplatin-eligible muscle-invasive bladder cancer and adjuvant pembrolizumab plus belzutifan in clear-cell renal-cell carcinoma at increased risk of recurrence.

ARTO supported further study of metastasis-directed therapy, JCOG1403 showed improved relapse-free survival with immediate intravesical pirarubicin, and TRAVERSE provided proof of concept for allogeneic CAR T-cell therapy in clear-cell RCC. CheckPRO, RADICAL, and PLANETTE did not support the experimental strategies evaluated.

Written by Ahmed Elalfy, MD, PhD